A phase 2 trial (NCT02423863) of intratumoral and intramuscular hiltonol alone or in combination with anti-PD-1/L1 in advanced, unresectable solid tumors, including melanoma, is now underway (Table 1). Here, PDCD1 is linked to melanoma.